- Home
- GLTO vs PNBK Comparison
GLTO vs PNBK Comparison
Compare GLTO & PNBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- PNBK
- Stock Information
- Founded
- GLTO 2011
- PNBK 1999
- Country
- GLTO Denmark
- PNBK United States
- Employees
- GLTO N/A
- PNBK N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- PNBK Major Banks
- Sector
- GLTO Health Care
- PNBK Finance
- Exchange
- GLTO Nasdaq
- PNBK Nasdaq
- Market Cap
- GLTO 7.5M
- PNBK 7.3M
- IPO Year
- GLTO 2020
- PNBK N/A
- Fundamental
- Price
- GLTO $4.70
- PNBK $2.11
- Analyst Decision
- GLTO Buy
- PNBK
- Analyst Count
- GLTO 1
- PNBK 0
- Target Price
- GLTO $10.00
- PNBK N/A
- AVG Volume (30 Days)
- GLTO 20.6K
- PNBK 44.4K
- Earning Date
- GLTO 11-01-2024
- PNBK 11-19-2024
- Dividend Yield
- GLTO N/A
- PNBK N/A
- EPS Growth
- GLTO N/A
- PNBK N/A
- EPS
- GLTO N/A
- PNBK N/A
- Revenue
- GLTO N/A
- PNBK $27,300,000.00
- Revenue This Year
- GLTO N/A
- PNBK N/A
- Revenue Next Year
- GLTO N/A
- PNBK N/A
- P/E Ratio
- GLTO N/A
- PNBK N/A
- Revenue Growth
- GLTO N/A
- PNBK 3.61
- 52 Week Low
- GLTO $4.40
- PNBK $1.38
- 52 Week High
- GLTO $23.50
- PNBK $4.70
- Technical
- Relative Strength Index (RSI)
- GLTO 26.70
- PNBK 50.41
- Support Level
- GLTO $4.40
- PNBK $2.26
- Resistance Level
- GLTO $5.42
- PNBK $2.45
- Average True Range (ATR)
- GLTO 0.37
- PNBK 0.36
- MACD
- GLTO -0.01
- PNBK -0.07
- Stochastic Oscillator
- GLTO 16.81
- PNBK 42.10
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About PNBK Patriot National Bancorp Inc.
Patriot National Bancorp Inc provides consumer and commercial banking services to individuals, small and medium-sized businesses, professionals, and municipalities in Fairfield and New Haven Counties in Connecticut and Westchester County, New York. Its products include checking accounts, savings accounts, money market accounts, time certificates of deposit, and individual retirement accounts. The Bank's lending portfolio is comprised of commercial mortgage and construction loans, commercial loans, home improvement loans, home equity lines of credit, and other personal loans. In addition, the Bank offers bank checks, money orders, automated teller machines, interactive teller machines, online and mobile banking, credit cards, and debit cards.